Soligenix (SNGX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.35, -1.92% vs the prior close of $0.36.
- Volume 217.77K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SNGX dips 1.9% to $0.35. Closed at $0.35, -1.92% vs the prior close of $0.36. Day range $0.35–$0.36, opened at $0.36.
SNGX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SNGX dips 1.9% to $0.35
- Closed at $0.35, -1.92% vs the prior close of $0.36. Day range $0.35–$0.36, opened at $0.36.
- Volume was 217.77K shares, 1.0x its 50-day average of 216.04K.
- Price is -5.6% vs its 50-day average ($0.37) and -51.8% vs its 200-day average ($0.73).
- 52-week range $0.28–$1.76; today's close sits at 5% of that range, 79.9% below the 52-week high.
Oct 15, 2026 — SNGX jumps 5.9% to $0.36
- Closed at $0.36, +5.88% vs the prior close of $0.34. Day range $0.34–$0.36, opened at $0.34.
- Volume was 163.20K shares, 0.8x its 50-day average of 216.06K.
- Price is -3.8% vs its 50-day average ($0.37) and -51.2% vs its 200-day average ($0.74).
- 52-week range $0.28–$1.76; today's close sits at 5% of that range, 79.5% below the 52-week high.
Oct 14, 2026 — SNGX jumps 3.0% to $0.34
- Closed at $0.34, +3.03% vs the prior close of $0.33. Day range $0.32–$0.35, opened at $0.32.
- Volume was 148.20K shares, 0.7x its 50-day average of 218.08K.
- Price is -9.3% vs its 50-day average ($0.37) and -54.2% vs its 200-day average ($0.74).
- 52-week range $0.28–$1.76; today's close sits at 4% of that range, 80.7% below the 52-week high.
Oct 13, 2026 — SNGX slides 5.7% to $0.33, a 3-month low
- Closed at $0.33, -5.71% vs the prior close of $0.35. Day range $0.33–$0.37, opened at $0.35.
- Volume was 267.40K shares, 1.2x its 50-day average of 216.68K.
- Price is -12.1% vs its 50-day average ($0.38) and -55.9% vs its 200-day average ($0.75).
- 52-week range $0.28–$1.76; today's close sits at 3% of that range, 81.2% below the 52-week high.
Oct 12, 2026 — SNGX dips 2.8% to $0.35
- Closed at $0.35, -2.78% vs the prior close of $0.36. Day range $0.35–$0.37, opened at $0.36.
- Volume was 61.80K shares, 0.3x its 50-day average of 221.95K — lighter than usual.
- Price is -7.1% vs its 50-day average ($0.38) and -53.6% vs its 200-day average ($0.75).
- 52-week range $0.28–$1.80; today's close sits at 5% of that range, 80.6% below the 52-week high.
Oct 9, 2026 — SNGX rises 2.9% to $0.36
- Closed at $0.36, +2.86% vs the prior close of $0.35. Day range $0.35–$0.37, opened at $0.35.
- Volume was 114.50K shares, 0.5x its 50-day average of 224.63K — lighter than usual.
- Price is -4.5% vs its 50-day average ($0.38) and -52.6% vs its 200-day average ($0.76).
- 52-week range $0.28–$1.97; today's close sits at 5% of that range, 81.7% below the 52-week high.
Oct 8, 2026 — SNGX ends flat (+0.0%) to $0.35, 4 down days in a row
- Closed at $0.35, +0.00% vs the prior close of $0.35. Day range $0.35–$0.36, opened at $0.36.
- Volume was 120.20K shares, 0.5x its 50-day average of 226.19K — lighter than usual.
- Price is -7.3% vs its 50-day average ($0.38) and -54.2% vs its 200-day average ($0.76).
- 52-week range $0.28–$1.97; today's close sits at 4% of that range, 82.2% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — SNGX dips 2.8% to $0.35, a 1-month low, 3 down days in a row
- Closed at $0.35, -2.78% vs the prior close of $0.36. Day range $0.35–$0.36, opened at $0.36.
- Volume was 62.80K shares, 0.3x its 50-day average of 233.29K — lighter than usual.
- Price is -7.3% vs its 50-day average ($0.38) and -54.5% vs its 200-day average ($0.77).
- 52-week range $0.28–$1.97; today's close sits at 4% of that range, 82.2% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — SNGX ends flat (+0.0%) to $0.36
- Closed at $0.36, +0.00% vs the prior close of $0.36. Day range $0.36–$0.36, opened at $0.36.
- Volume was 185.60K shares, 0.8x its 50-day average of 234.47K.
- Price is -4.7% vs its 50-day average ($0.38) and -53.4% vs its 200-day average ($0.77).
- 52-week range $0.28–$1.97; today's close sits at 5% of that range, 81.7% below the 52-week high.
Oct 5, 2026 — SNGX dips 2.7% to $0.36
- Closed at $0.36, -2.70% vs the prior close of $0.37. Day range $0.36–$0.37, opened at $0.36.
- Volume was 107.90K shares, 0.5x its 50-day average of 235.34K — lighter than usual.
- Price is -4.7% vs its 50-day average ($0.38) and -53.7% vs its 200-day average ($0.78).
- 52-week range $0.28–$1.97; today's close sits at 5% of that range, 81.7% below the 52-week high.
Oct 2, 2026 — SNGX rises 2.8% to $0.37
- Closed at $0.37, +2.78% vs the prior close of $0.36. Day range $0.36–$0.37, opened at $0.37.
- Volume was 146.50K shares, 0.6x its 50-day average of 242.89K.
- Price is -2.1% vs its 50-day average ($0.38) and -52.8% vs its 200-day average ($0.78).
- 52-week range $0.28–$1.97; today's close sits at 5% of that range, 81.2% below the 52-week high.
SNGX latest news & SEC filings
Every SEC filing by or about SNGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 7, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 7, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 7, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$1.99M (prior year -$2.70M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.12 (prior year -$0.82) (loss narrowed vs Jun 30, 2025)
Aug 3, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Aug 3, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 3, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Things to know before you trade SNGX
- Last results release: Aug 12, 2016 (8-K Item 2.02). Previous ones: Aug 21, 2013, May 8, 2013, Aug 10, 2012. Based on that rhythm, the next report is likely around Nov 11, 2016 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.19% (largest 5.9%).
- Liquidity: about 190.91K shares (≈$67.41K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.35 vs a range of $0.28–$1.76 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Christopher J Schaber bought 15,132 shares on Oct 2, 2025.
- Latest filings: 8-K Sep 21, 2026; 10-Q Aug 7, 2026; 8-K Jun 26, 2026.
- Share count: 21.77M shares outstanding (Jul 31, 2026), +407.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SNGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.36 | 0.36 | 0.35 | 0.35 | 217.77K |
| Oct 15, 2026 | 0.34 | 0.36 | 0.34 | 0.36 | 163.20K |
| Oct 14, 2026 | 0.32 | 0.35 | 0.32 | 0.34 | 148.20K |
| Oct 13, 2026 | 0.35 | 0.37 | 0.33 | 0.33 | 267.40K |
| Oct 12, 2026 | 0.36 | 0.37 | 0.35 | 0.35 | 61.80K |
| Oct 9, 2026 | 0.35 | 0.37 | 0.35 | 0.36 | 114.50K |
| Oct 8, 2026 | 0.36 | 0.36 | 0.35 | 0.35 | 120.20K |
| Oct 7, 2026 | 0.36 | 0.36 | 0.35 | 0.35 | 62.80K |
| Oct 6, 2026 | 0.36 | 0.36 | 0.36 | 0.36 | 185.60K |
| Oct 5, 2026 | 0.36 | 0.37 | 0.36 | 0.36 | 107.90K |
| Oct 2, 2026 | 0.37 | 0.37 | 0.36 | 0.37 | 146.50K |
| Oct 1, 2026 | 0.36 | 0.37 | 0.36 | 0.36 | 45.30K |
| Sep 30, 2026 | 0.37 | 0.37 | 0.36 | 0.36 | 90.30K |
| Sep 29, 2026 | 0.38 | 0.38 | 0.36 | 0.37 | 406.60K |
| Sep 28, 2026 | 0.38 | 0.38 | 0.38 | 0.38 | 135.00K |
| Sep 25, 2026 | 0.39 | 0.39 | 0.38 | 0.38 | 72.70K |
| Sep 24, 2026 | 0.38 | 0.39 | 0.38 | 0.39 | 228.60K |
| Sep 23, 2026 | 0.39 | 0.39 | 0.38 | 0.39 | 372.70K |
| Sep 22, 2026 | 0.39 | 0.39 | 0.38 | 0.39 | 529.80K |
| Sep 21, 2026 | 0.38 | 0.38 | 0.37 | 0.37 | 341.30K |
About Soligenix
Soligenix (SNGX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 812796.
SNGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Anthony Gregg Lapointe | Director | Sep 18, 2026 |
| Diane L. Parks | Director | Sep 18, 2026 |
| Robert J. Rubin | Director | Sep 18, 2026 |
| Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | Dec 12, 2025 |
| Jerome B Zeldis | Director | Sep 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Oreola Donini | CSO | Dec 12, 2025 |
| Jonathan L. Guarino | CFO | Dec 12, 2025 |
| Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | Dec 12, 2025 |
| Richard Straube | CMO (Consulting) | Dec 12, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Oct 2, 2025 | Christopher J Schaber | Buy | 15,132 | $1.32 |
| Oct 2, 2025 | Christopher J Schaber | Buy | 15,132 | $1.32 |
| Oct 2, 2025 | Christopher J Schaber | Buy | 15,132 | $1.32 |
| Oct 2, 2025 | Christopher J Schaber | Buy | 15,132 | $1.32 |
SNGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-11.08M | -2.14 | $-10.27M |
| Dec 31, 2024 | $119.37K | $-8.27M | -4.98 | $-8.40M |
| Dec 31, 2023 | $839.36K | $-6.14M | -12.66 | $-8.60M |
| Dec 31, 2022 | $948.91K | $-13.80M | -4.81 | $-12.65M |
| Dec 31, 2021 | $824.27K | $-12.55M | -4.69 | $-11.74M |
Latest balance sheet: total assets $10.50M, total liabilities $3.85M, cash $22.88M (as of Jun 30, 2026).
SNGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2016 | 8-K Item 2.02 (results) | — |
| Aug 21, 2013 | 8-K Item 2.02 (results) | — |
| May 8, 2013 | 8-K Item 2.02 (results) | — |
| Aug 10, 2012 | 8-K Item 2.02 (results) | — |
| May 15, 2012 | 8-K Item 2.02 (results) | — |
| Aug 12, 2011 | 8-K Item 2.02 (results) | — |
| May 13, 2011 | 8-K Item 2.02 (results) | — |
| Mar 29, 2011 | 8-K Item 2.02 (results) | — |
| Nov 16, 2010 | 8-K Item 2.02 (results) | — |
| Aug 13, 2010 | 8-K Item 2.02 (results) | — |
| May 17, 2010 | 8-K Item 2.02 (results) | — |
| Apr 1, 2010 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SNGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.